Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL49195 | 1.00 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL819653 | 1.00 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL49353 | 1.00 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL7647781 | 1.00 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL7644168 | 1.00 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL1679057 | 0.96 | EPHX1 (0.47) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL1678725 | 0.96 | EPHX1 (0.47) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL1679055 | 0.96 | EPHX1 (0.47) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL49819 | 0.96 | EPHX1 (0.44) | EPHX1HIF1AALDH1A1SIGMAR1KMT2A | |
| SCHEMBL1678970 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198487-B2 | Method for lithium exchange reactions | LONZA AG (CH) | 2012-06-12 | — | — | US | disclosed |
| EP-2109616-B1 | METHOD FOR LITHIUM EXCHANGE REACTIONS | LONZA AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| US-20100113839-A1 | METHOD FOR LITHIUM EXCHANGE REACTIONS | LONZA AG (CH) | 2010-05-06 | — | — | US | disclosed |
| EP-2109616-A1 | METHOD FOR LITHIUM EXCHANGE REACTIONS | LONZA AG (CH) | 2009-10-21 | — | — | EP | disclosed |
| WO-2008095646-A1 | METHOD FOR LITHIUM EXCHANGE REACTIONS | LONZA AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| EP-1956023-A1 | Method for lithium exchange reactions | LONZA AG (CH) | 2008-08-13 | — | — | EP | disclosed |
| US-5245069-A | Reacting a phosphoryl halide and a phenol in the presence of a dialkylaminopyridine and an arylphosphorodihalidate | MERCK & CO., INC. (US) | 1993-09-14 | — | — | US | disclosed |
| EP-0167817-B1 | 8-Alkylthio-2-piperazino-pyrimido[5,4-d]pyrimidines, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1989-09-20 | — | — | EP | disclosed |
| US-4845261-A | Process for bis(substituted phenyl) phosphorohalidates | MERCK & CO., INC. (US) | 1989-07-04 | — | — | US | disclosed |
| US-4714698-A | ANTITUMOR, ANTICOAGULANT | DR. KARL THOMAE GMBH (DE) | 1987-12-22 | — | — | US | disclosed |
| EP-0167817-A1 | 8-Alkylthio-2-piperazino-pyrimido[5,4-d]pyrimidines, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113839-A1 | METHOD FOR LITHIUM EXCHANGE REACTIONS | SLC6A5, SLC6A9, SLC6A6 | EPHX1 3461/4885HIF1A 4358/4885ALDH1A1 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.